Although Cobalis’ current planned research is focused on studying the effects of cyanocobalamin (the active ingredient in PreHistin™) on the reduction of symptoms associated with seasonal and perennial allergic rhinitis, we also plan to sponsor clinical trials relating to other immunoglobulin-E (IgE)-mediated allergic diseases to expand our product line.

These supplemental indications include:

• Pediatric dosing for seasonal allergic rhinitis
• Allergic asthma
• Food allergies (including peanut)
• IgE-mediated skin disorders (dermatitis, chronic urticaria, eczema, psoriasis)
• Allergic and migraine headache

PreHistin™ is intended to become the first-ever medication aimed specifically at rectifying imbalances in the immune system that trigger the over-production of allergy symptom-causing substances, including histamines. By preventing or reducing the over-production of histamines before they are released, the need to block the symptom-causing effects of histamine is eliminated, as is the need to rely on antihistamines.

Cobalis’ approach makes good marketing sense when compared to the current paradigm of blocking the action of already-produced symptom-causing substances with antihistamines or other drugs, which often result in debilitating and uncomfortable side-effects. PreHistin™, as a preventative approach to allergic disease, becomes The World’s First Pre-Histamine™.

Our patents have broad claims covering all of the above-mentioned allergic diseases. The patents describe the use of cobalamin for reducing “…the symptoms and IgE antibodies associated with allergic diseases.”